07:00 , Jun 16, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: CD40; Fcγ receptor IIb (FCγR2B; CD32B); FCγR2A (CD32A)

Cancer INDICATION: Cancer In vitro and mouse studies suggest a CD40-targeting mAb with greater affinity for FCγR2B than for FCγR2A could help treat cancer. In in vitro binding assays, a variant of the CD40-agonizing mAb...
07:00 , Apr 15, 2013 |  BC Week In Review  |  Company News

VLST cancer, autoimmune, inflammation news

VLST said it would reduce headcount by 12 (70%) to five by year end to focus on cancer compound CP-870,893 , which it licensed from Pfizer Inc. (NYSE:PFE, New York, N.Y.) in August. The anti-...
07:00 , Sep 3, 2012 |  BC Week In Review  |  Company News

VLST, Pfizer deal

Pfizer granted VLST worldwide rights to cancer compound CP-870,893 . The anti- CD40 mAb has completed five Phase I trials. VLST expects to start additional Phase I testing in about 6-9 months to confirm dosing...
23:44 , Aug 31, 2012 |  BC Extra  |  Company News

VLST in-licenses Pfizer's anti-CD40 mAb

Pfizer Inc. (NYSE:PFE) granted VLST Corp. (Seattle, Wash.) worldwide rights to cancer compound CP-870,893 . The anti- CD40 mAb has completed five Phase I trials. VLST expects to start additional Phase I testing in about...
07:00 , Oct 17, 2011 |  BioCentury  |  Product Development

Tremelimumab, take three

Three years after Pfizer Inc. discontinued development of tremelimumab for melanoma, AstraZeneca plc 's MedImmune LLC unit has in-licensed the mAb. Poor design may have tripped up Pfizer's Phase III, but given that two new...